Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 8, 2026, 10:30 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1345–1368 of 5,059 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Capsule 2 Clear all

Conditions: Minority Stress, Psychological Stress, Anxiety
Interventions: Ashwagandha Root Extract, Placebo Capsule; Dietary Supplement · Other
Lead sponsor: SF Research Institute, Inc.; Network
Eligibility: 18 Years to 45 Years
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Menopause, Hypertension
Interventions: L-Citrulline, Placebo; Dietary Supplement
Lead sponsor: Texas Tech University; Other
Eligibility: 50 Years to 70 Years · Female only
Enrollment: 19 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Lubbock, Texas

Conditions: Alzheimer's Disease, Oxidative Stress, Dementia, Hyperlipidemia, Inflammation
Interventions: Fish Oil, Lipoic Acid, Fish Oil Placebo, Lipoic Acid Placebo; Dietary Supplement · Other
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 55 Years and older
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Invasive Fungal Infections
Interventions: SUBA itraconazole, Conventional itraconazole; Drug
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 19 Years and older
Enrollment: 88 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 11
States / cities: Birmingham, Alabama • Tucson, Arizona • Sacramento, California + 7 more

Conditions: Triple Negative Breast Cancer, Inflammatory Breast Cancer Stage IV
Interventions: Bemcentinib; pembrolizumab; Drug
Lead sponsor: BerGenBio ASA; Industry
Eligibility: 18 Years and older
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 5
States / cities: Duarte, California • San Diego, California • Kansas City, Missouri + 2 more

Conditions: Cocaine Dependence
Interventions: Doxazosin, Placebo; Drug · Other
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 18 Years to 64 Years
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Attention Deficit Hyperactivity Disorder (ADHD)
Interventions: SHP465, Placebo; Drug
Lead sponsor: Shire; Industry
Eligibility: 6 Years to 17 Years
Enrollment: 264 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 36
States / cities: Dothan, Alabama • Orange, California • San Diego, California + 31 more

Conditions: Vitiligo
Interventions: Ritlecitinib, Ritlecitinib 100 mg, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 12 Years and older
Enrollment: 394 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 22
States / cities: Encinitas, California • Huntington Beach, California • Los Angeles, California + 16 more

Conditions: Diabetes Mellitus, Type 2
Interventions: Placebo, Canagliflozin, Sitagliptin, Metformin, Pioglitazone; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 344 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 41
States / cities: Anniston, Alabama • Phoenix, Arizona • Tucson, Arizona + 38 more

Conditions: Healthy Adult
Interventions: L-histidine, Monosodium glutamate (MSG), Sodium chloride (NaCl); Dietary Supplement
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Psychosis Associated With Alzheimer's Disease
Interventions: KarXT; Drug
Lead sponsor: Karuna Therapeutics, Inc., a Bristol Myers Squibb company; Industry
Eligibility: 55 Years to 90 Years
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 148
States / cities: Homewood, Alabama • Chandler, Arizona • Gilbert, Arizona + 92 more

Conditions: Gastroesophageal Reflux Disease (GERD)
Interventions: Rabeprazole ER, Ranitidine; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 4
States / cities: Moline, Illinois

Conditions: Other Acute Postoperative Pain
Interventions: Indomethacin, Celecoxib, Placebo; Drug
Lead sponsor: Iroko Pharmaceuticals, LLC; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 462 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012
U.S. locations: 4
States / cities: Phoenix, Arizona • Pasadena, Maryland • Austin, Texas + 1 more

Conditions: Acute Kidney Injury
Interventions: Creatine Monohydrate, Creatine Ethyl Ester; Dietary Supplement
Lead sponsor: Beth Israel Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 1
States / cities: New York, New York

Conditions: Pain
Interventions: Lidocaine, Bupivacaine; Drug
Lead sponsor: University of Maryland; Other
Eligibility: 18 Years to 65 Years
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Chronic Obstructive Pulmonary Disease (COPD)
Interventions: indacaterol/glycopyrrolate, indacaterol, placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 40 Years and older
Enrollment: 154 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 3
States / cities: St Louis, Missouri • Charlotte, North Carolina • Raleigh, North Carolina

Conditions: Metastatic Pancreatic Cancer
Interventions: Azeliragon; Drug
Lead sponsor: Cantex Pharmaceuticals; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 6
States / cities: Los Angeles, California • Boca Raton, Florida • Eugene, Oregon + 3 more

Conditions: Chronic Hepatitis C
Interventions: BMS-791325, Placebo; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 5
States / cities: Anaheim, California • Cypress, California • St Louis, Missouri + 2 more

Conditions: Aspergillosis, Invasive Fungal Infections
Interventions: isavuconazole; Drug
Lead sponsor: Astellas Pharma Inc; Industry
Eligibility: 18 Years and older
Enrollment: 149 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2016
U.S. locations: 24
States / cities: Birmingham, Alabama • Duarte, California • Sacramento, California + 19 more

Conditions: Myelodysplastic Syndrome
Interventions: rigosertib; Drug
Lead sponsor: Traws Pharma, Inc.; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 1
States / cities: New York, New York

Conditions: OSA, Obstructive Sleep Apnea
Interventions: Acetazolamide, Eszopiclone, Placebo, Venlafaxine; Drug
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years to 65 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 2
States / cities: La Jolla, California

Conditions: Primary Sclerosing Cholangitis (PSC)
Interventions: LB-P8 low-dose, LB-P8 high-dose, Placebo; Drug
Lead sponsor: LISCure Biosciences; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 87 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 7
States / cities: Sacramento, California • Aurora, Colorado • Iowa City, Iowa + 4 more

Conditions: Cardioprotective Levels
Interventions: Omega-3; Dietary Supplement
Lead sponsor: Bucci Laser Vision Institute; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Wilkes-Barre, Pennsylvania

Conditions: Healthy
Interventions: Topiramate Sprinkle Capsules 25 mg, Topamax® Sprinkle Capsules 25 mg; Drug
Lead sponsor: Mylan Pharmaceuticals Inc; Industry
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005
U.S. locations: 1
States / cities: Morgantown, West Virginia

Search by objective public record fields.

Effect of Ashwagandha Root Extract on Stress, Anxiety, and Sleep Quality in Adults Experiencing Minority Stress

2 Weeks of Citrulline Supplementation on Arterial Function in Postmenopausal Women With Elevated Blood Pressure or Hypertension

Fish Oil and Alpha Lipoic Acid in Treating Alzheimer's Disease

Endemic Mycoses Treatment With SUBA-itraconazole vs Itraconazole

Bemcentinib (BGB324) in Combination With Pembrolizumab in Patients With TNBC

The Efficacy of Doxazosin for Cocaine Users

Safety and Efficacy Study of SHP465 in Children and Adolescents Aged 6-17 Years With Attention-Deficit Hyperactivity Disorder (ADHD)

A 52-Week Study to Learn About the Safety and Effects of Ritlecitinib in Participants With Nonsegmental Vitiligo

The CANTATA-MP Trial (CANagliflozin Treatment and Trial Analysis - Metformin and Pioglitazone)

Effect of Monosodium Glutamate on Microbiome-Derived Imidazole Propionate Production in Healthy Volunteers

Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)

Rabeprazole Extended-Release 50 mg vs. Ranitidine 150 mg for Maintenance of Healed Erosive Gastroesophageal Reflux Disease (GERD)

Study of Indomethacin Capsules to Treat Pain Following Bunionectomy

Effect of Creatine on Serum and Urine Creatinine

Bupivacaine Versus Lidocaine on Inflammatory Regulation

Efficacy and Safety of QVA149 in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Study of Effect of Azeliragon in Patients Refractory to Prior Treatment of Metastatic Pancreatic Cancer

A Single Ascending Dose Study of BMS-791325 in HCV Infected Subjects

Isavuconazole in the Treatment of Renally Impaired Aspergillosis and Rare Fungi

Three Dosing Schedules of Oral Rigosertib in MDS Patients

Combination Drug-Therapy for Patients With Untreated Obstructive Sleep Apnea

A Study to Assess the Safety and Efficacy of LB-P8 in Patients With PSC

Is Omega-3 Fatty Acid Red Blood Cell (RBC) Saturation Product Dependent?

Fed Study of Topiramate Sprinkle Capsules 25 mg and Topamax® Sprinkle Capsules 25 mg